ArticleJournal of clinical microbiology2015
Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period.
Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 42 citations in OpenAlex.
- Vitamin D and prebiotics for intestinal health in cystic fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 x 2 trial of administration of prebiotics and cholecalciferol (vitamin DContemporary clinical trials communications · 2024Article
- Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 × 2 trial of administration of prebiotics and cholecalciferol (vitamin DmedRxiv : the preprint server for health sciences · 2024Article
- 16S rRNA-Based Microbiota Profiling Assists Conventional Culture Analysis of Airway Samples from Pediatric Cystic Fibrosis Patients.Microbiology spectrum · 2023Article
- A population-level strain genotyping method to study pathogen strain dynamics in human infections.JCI insight · 2021Article
- A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial.Transplantation and cellular therapy · 2021Article
- Automated design of synthetic microbial communities.Nature communications · 2021Article
- Article
- The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and Inter-Kingdom Crosstalks.Frontiers in cellular and infection microbiology · 2020Review
- Article
- An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients.Paediatric drugs · 2018Review
- Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.Expert review of respiratory medicine · 2018Review
- "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.Journal of clinical microbiology · 2018Article
- How can the cystic fibrosis respiratory microbiome influence our clinical decision-making?Current opinion in pulmonary medicine · 2017Review
- Episodic oral antibiotic use in CF: Discordance between the electronic medical record and self-report.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2016Article
- Analysis of the association between host genetics, smoking, and sputum microbiota in healthy humans.Scientific reports · 2016Article
- Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens.Journal of clinical microbiology · 2016Article
- Article
- Novel aspects of pathogenesis and regeneration mechanisms in COPD.International journal of chronic obstructive pulmonary disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolution of pulmonary disease in cystic fibrosis (CF) usually begins when bacteria get trapped in mucus in the lungs and become established as a chronic infection. While most CF patients experience periods of stability, pulmonary exacerbations (PEs) can occur multiple times per year and result in permanent damage to the lungs. Little is known of the shift from a period of stability to a PE, but this shift is likely to be attributed to changes in the bacterial community. Here, we identified changes in the lung microbiota to determine if they reflect patient health, indicate the onset of exacerbations, or are related to antibiotic treatment. In contrast to most bacterial studies on CF, we collected weekly samples from an adult CF patient over a period of 3 years and performed quantitative PCR (qPCR) and Illumina sequencing on those samples. While many DNA-based studies have shown the CF microbiota to be relatively stable, we observed an increase in the total bacterial abundance over time (P < 0.001), while the number of different taxa (bacterial richness) and the number of different taxa and their abundances (diversity) significantly decreased over time (P < 0.03), which was likely due to repeated antibiotic exposure. Using genus-specific primers with qPCR, we observed an increase in the abundance of Burkholderia multivorans, a CF-associated pathogen, prior to the occurrence of a PE (P = 0.006). Combining these DNA-based techniques with frequent sampling identified a potential initiator for exacerbations and described a response of the CF microbiota to time and antibiotic treatment not observed in previous CF microbiota studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.